Related Experiment Video
Updated: Jun 22, 2026
An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid
Seong Keun Yoo1, Young Shin Song2, Young Joo Park3,4
1Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Abstract:
Anaplastic thyroid cancer (ATC) is a lethal human cancer with a 5-year survival rate of less than 10%. Recently, its genomic and transcriptomic characteristics have been extensively elucidated over 5 years owing to advance in high throughput sequencing. These efforts have extended molecular understandings into the progression mechanisms and therapeutic vulnerabilities of aggressive thyroid cancers. In this review, we provide an overview of genomic and transcriptomic alterations in ATC and poorly-differentiated thyroid cancer, which are distinguished from differentiated thyroid cancers. Clinically relevant genomic alterations and deregulated signaling pathways will be able to shed light on more effective prevention and stratified therapeutic interventions for affected patients.
Insights
Anaplastic thyroid cancer (ATC) and poorly-differentiated thyroid cancer exhibit distinct genomic and transcriptomic alterations. Understanding these molecular changes offers new avenues for targeted therapies and improved patient outcomes.
Area of Science:
- Oncology
- Genomics
- Molecular Biology
Background:
- Anaplastic thyroid cancer (ATC) is a highly lethal malignancy with a poor prognosis.
- Recent advancements in high-throughput sequencing have significantly improved our understanding of thyroid cancer genomics.
Purpose of the Study:
- To review the genomic and transcriptomic alterations in ATC and poorly-differentiated thyroid cancer.
- To highlight molecular insights into cancer progression and therapeutic vulnerabilities.
- To identify clinically relevant alterations for improved prevention and treatment strategies.
Main Methods:
- Comprehensive review of existing literature on genomic and transcriptomic studies in thyroid cancer.
- Analysis of high-throughput sequencing data to identify key molecular alterations.
- Integration of molecular findings with clinical relevance for therapeutic implications.
Main Results:
- Genomic and transcriptomic landscapes of ATC and poorly-differentiated thyroid cancer differ significantly from differentiated thyroid cancers.
- Specific deregulated signaling pathways and clinically relevant genomic alterations have been identified.
- These molecular insights provide a foundation for understanding disease progression.
Conclusions:
- Elucidation of genomic and transcriptomic alterations in aggressive thyroid cancers is crucial.
- Targeted therapeutic interventions can be developed based on identified molecular vulnerabilities.
- Further research into these alterations will guide personalized medicine approaches for thyroid cancer patients.
